ShareHope Medicine (8403) reported revenue of NT$362.6 million for Oct 2026, -5.9% year on year and -15.3% from the previous month. Revenue for Jan–Oct 2026 was NT$3.86 billion (+6.8% year on year).
In Oct 2026, it ranked No. 26 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$362.6 million | -5.9% | -15.3% |
| Sep 2026 | NT$428.1 million | +16.3% | +7.6% |
| Aug 2026 | NT$397.9 million | +8.6% | -3.5% |
| Jul 2026 | NT$412.2 million | +10.6% | -5.3% |
| Jun 2026 | NT$435.1 million | +12.5% | +18.4% |
| May 2026 | NT$367.6 million | +9.7% | -4.5% |
| Apr 2026 | NT$385 million | +8.6% | -2.7% |
| Mar 2026 | NT$395.9 million | +1.0% | +34.8% |
| Feb 2026 | NT$293.6 million | -3.3% | -23.8% |
| Jan 2026 | NT$385.2 million | +9.4% | -2.7% |
| Dec 2025 | NT$396 million | +5.7% | +15.0% |
| Nov 2025 | NT$344.2 million | -6.0% | -10.7% |
| Oct 2025 | NT$385.5 million | +4.0% | +4.7% |
| Sep 2025 | NT$368.2 million | -2.9% | +0.5% |
| Aug 2025 | NT$366.4 million | -4.5% | -1.7% |
| Jul 2025 | NT$372.7 million | -2.7% | -3.6% |
| Jun 2025 | NT$386.7 million | -0.4% | +15.4% |
| May 2025 | NT$335.3 million | -10.6% | -5.5% |
| Apr 2025 | NT$354.6 million | +6.6% | -9.6% |
| Mar 2025 | NT$392.1 million | +20.3% | +29.2% |
| Feb 2025 | NT$303.5 million | +10.6% | -13.8% |
| Jan 2025 | NT$352 million | -5.4% | -6.0% |
| Dec 2024 | NT$374.5 million | -3.1% | +2.3% |
| Nov 2024 | NT$366.1 million | +8.4% | -1.3% |
| Oct 2024 | NT$370.8 million | +8.0% | -2.2% |
Jan–Oct 2026 cumulative: NT$3.86 billion (+6.8% YoY)
Other Biotech & Medical companies
Compare with peers: ShareHope Medicine vs PEC / ShareHope Medicine vs Lotus Pharm / ShareHope Medicine vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16